Parabolic Drugs Limited– IPO Note - ANS Pvt. Ltd.

More documents

Recommendations

Info

Issue DetailsSectorPharmaceuticalIssue Size 26,666,667QIBs * 13,083,334Non-Institutional* 3,925,000Retail* 9,158,333Face Value Rs. 10Price Band # Rs. 75-85BRLMsAvendus CapitalICICI Securities LtdSPA MerchantRegistrarLink Intime IndiaCompany Address:Corporate Office9AB, Taimoor Nagar,New Friends Colony,New Delhi 110 065,India.Tel: + (91 11) 6517 6840Fax: + (91 11) 2633 2660Website: www.parabolicdrugs.com* Minimum allotmentRATINGS: CARE has given an IPO rating of GRADE 2 to the issue suggesting belowaverage fundamentals for the company, and BRW has given an IPO rating ofGRADE 3 to the issue suggesting average fundamentals for the company.Parabolic Drugs Limited is one of the fast growing API (Active Pharmaceutical Ingredients) andAPI intermediate manufacturing and marketing company in the SME segment, with increasinginternational presence and a strong R&D foundation, based at Chandigarh, India.Commissioned in 1998, PDL has two fully functional, state of the art manufacturing units, aWHO-GMP certified Unit based in Derabassi (Punjab) and a USFDA accredited manufacturingplant at Panchkula, (Haryana) respectively.Over the decade, PDL’s management has created a scalable business model in the API & APIIntermediates segment to offer a product basket of Semi Synthetic Penicillin’s (oral & Sterile)and Cephalosporin’s (oral) and Cephalosporin Sterile. The Company commissioned a 6-APAfacility at Panchkula, Haryana in FY 2005 which is approved by USFDA for supply of the productto US Markets.PDL has consistently registered a growth rate of 70% on year on year basis over the last threeyears, both in its top line and bottom line. The company has managed to maintain its EBIDTA at15% in last three years during this period.This phenomenal growth has been driven by a vision of INR 1000 Crores, Global API and CRAMSCompany by the year 2011-2012 under the chairmanship of Mr. Pranav Gupta, a young anddynamic first generation entrepreneur. The Company has set forth huge expansion plansincluding inorganic growth and foray into Custom synthesis & Contract Manufacture.PDL’s long-term strategy includes expanding product basket to include Cephalosporin (Sterile)to its existing portfolio and become a preferred supplier to large global pharmaceutical playersfor supplying APIs and API intermediates in the regulated markets of US and Europe. TheCompany has recently commenced its CRAMS business and is fast expanding its marketpenetration in the Middle East & European markets, in both API and CRAMS segments.PDL is moving step by step, in a phased manner to be able to achieve its Vision of being a worldclass supplier of API and Custom synthesis services of the highest quality.
The net issue proceeds will be used for following objectives:The Net Proceeds of the Fresh Issue are proposed to be utilized by us for financing thefollowing objects:1. Multi-purpose Block III at Derabassi;2. Sterile cephalosporin plant at Derabassi;3. Establishment of Chachrauli plant;4. Investment in our Subsidiary;5. Repayment / prepayment of identified loan facilities; and6. General corporate purposes.Source: Company RHP
Page 4 and 5: INDUSTRY OUTLOOKINDIAN PHARMACEUTIC
Page 6 and 7: The Indian CRAMS IndustryIndia is e
Page 8 and 9: ConcernsNegative Operating Cash flo
Page 10 and 11: FINANCIAL HIGHLIGHTS1. Total income
Page 12 and 13: -Die Wirtschaftsgebäude: die Bauh

Parabolic Drugs Limited– IPO Note - ANS Pvt. Ltd.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?